University of Oxford - Articles and news items

Researchers discover severe side effects of approved multiple sclerosis medication

Industry news / 20 January 2017 / Niamh Marriott, Digital Editor

The multiple sclerosis therapy alemtuzumab can trigger severe, unpredictable side effects…

Combined HIV and hepatitis C virus vaccination a step closer

Industry news / 13 April 2016 / Victoria White, Digital Content Producer

A study has shown that the ‘prime boost’ approach is compatible with co-administration of vectors encoding for HIV and HCV antigens…

Repurposed ebselen shows promise in bipolar trial

Industry news / 9 December 2015 / Victoria White

In a small trial, where healthy adult volunteers were given a course of ebselen, the results showed that ebselen had similar effects on the brain to lithium…

Virus-carrying mosquitoes are more widespread than ever

Industry news / 30 June 2015 / Victoria White

Scientists behind the first global distribution maps of two species of dengue and chikungunya-carrying mosquitoes warn they are spreading to new areas…

The determination of structural changes of biopharmaceuticals during Freeze-Drying using Fourier Transform Infrared Spectroscopyb

Issue 2 2009, Past issues / 20 March 2009 /

Peptides and proteins are powerful active therapeutic ingredients used in a wide variety of serious conditions and illnesses such as diabetes, arthritis or cancer. The application of these so-called biopharmaceuticals has been rapidly increasing since the middle of the 1990s, facilitated by improvements in modern recombinant DNA technology and biotechnological manufacturing. The worldwide sales of the biotech drug market grew from 43 billion US$ in 2003 to over 75 billion US$ in 2007 according to a recent IMS Health market analysis. The major challenge in the development of stable protein formulations and dosage forms is to ensure their process and shelf life stability.

RNAi therapeutics for neurodegenerative disease: challenges and prospects

Issue 2 2008, Past issues / 19 March 2008 /

The early 21st century has seen a revolution in RNA biology, bringing with it the prospect of a new class of medicines based on RNA. What are the prospects for developing these RNA-based medicines for the growing medical problem of neurodegenerative disease and what are the challenges to making these new medicines work successfully within the complex environment of the nervous system? Recent progress on RNA silencing of neurodegenerative disease targets and RNAi delivery to the nervous system is encouraging and suggests that clinical evaluation of these therapeutic agents is realistic within the next few years.

Spray-freeze-drying in the manufacture of pharmaceuticals

Issue 3 2007 / 23 May 2007 / Heiko A. Schiffter, Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford

Over the last decade, the development of new drug delivery methods and devices for dry powder inhalation1, needle-free intradermal powder injection2 or sustained parenteral drug delivery3 has led to an increasing demand for powder formulations incorporating an active pharmaceutical ingredient (API)4,5.

Structural genomics, the practical way

Issue 4 2006, Past issues / 20 July 2006 / Frank von Delft, Principle Investigator, Protein Crystallography Group, Structural Genomics Consortium, University of Oxford

The Structural Genomics Consortium (SGC) is an internationally funded collaboration with sites in three countries and a three-year goal of solving the 3-dimensional structures of more than 380 human proteins with particular medical relevance, and placing them in the public domain without restrictions. The structures should prove an invaluable resource for research into the proteins’ functions and their use as targets for therapeutic intervention; in this the SGC is a successor to the Human Genome Project (HGP). The SGC has benefited from adopting existing, commercialised robotics, and is subsequently working with vendors to adjust performance with its needs.

Options for quantitative analysis by real-time PCR

Issue 4 2005, Past issues / 11 November 2005 / Gareth Elvidge, PhD, Genomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford

The expansion of microarray-based gene expression studies has led to an increase in demand for gene-specific PCR-based methods for independent validation of results. Although a number of technologies are available to meet this requirement the most popular is currently real-time PCR.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...